212 related articles for article (PubMed ID: 36192730)
1. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
Liu W; Zhang Q; Zhang T; Li L; Xu C
World J Surg Oncol; 2022 Oct; 20(1):333. PubMed ID: 36192730
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
5. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Muss HB; Tamura K
Oncologist; 2019 Jul; 24(7):e565-e573. PubMed ID: 30552160
[TBL] [Abstract][Full Text] [Related]
7. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
[TBL] [Abstract][Full Text] [Related]
12. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.
Xu Z; Liang J; Fu R; Yang L; Xin Chen Y; Ren W; Lu Y; Qiu X; Gu Q
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):640-651. PubMed ID: 37563075
[TBL] [Abstract][Full Text] [Related]
13. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
14. Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Madala S; Rasul R; Singla K; Sison CP; Seetharamu N; Castellanos MR
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):799-809. PubMed ID: 35400597
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
16. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
18. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
Luo H; Song G; Wang D; Li M; Dai N
Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
[TBL] [Abstract][Full Text] [Related]
19. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Tong ZQ; Wu DY; Liu D; Dong M
Eur J Clin Pharmacol; 2021 Aug; 77(8):1079-1088. PubMed ID: 33564898
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
